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Abstract
Background: Telomerase plays an important role in cell proliferation and carcinogenesis and is believed to be a
good target for anti-cancer drugs. Elimination of template function of telomerase RNA may repress the telomerase
activity.
Methods: A pseudo-knotted HDV ribozyme (g.RZ57) directed against the RNA component of human telomerase
(hTR) was designed and synthesized. An in vitro transcription plasmid and a eukaryotic expression plasmid of
ribozyme were constructed. The eukaryotic expression plasmid was induced into heptocellular carcinoma 7402
cells, colon cancer HCT116 cells and L02 hepatocytes respectively. Then we determine the cleavage activity of
ribozyme against human telomerase RNA component (hTR) both in vitro and in vivo, and detect telomerase
activity continuously.
Results: HDV ribozyme showed a specific cleavage activity against the telomerase RNA in vitro. The maximum
cleavage ratio reached about 70.4%. Transfection of HDV ribozyme into 7402 cells and colon cancer cells HCT116
led to growth arrest and the spontaneous apoptosis of cells, and the telomerase activity dropped to 10% of that
before.
Conclussion: HDV ribozyme (g.RZ57) is an effective strategy for gene therapy.
Background
Immortalized and malignant tumor cells are character-
ized by unlimited cell proliferation and programmed cell
death (apoptosis). It has been demonstrated that malig-
nant transformation occurs when the telomerase in nor-
mal cell is activated [1,2].
Telomerase activity is found in almost all malignant
tumors [3]. Human telomerase RNA (hTR) is associated
with the activity of telomerase, immortalized cancer
cells retain the highest level of hTR [4,5]. In recent
years, hammerhead ribozymes were used to inhibit the
telomerase activity by targeting the template region of
telomerase RNA in malignant tumors [6,7]. Yet, there is
no report about HDV ribozyme for inhibition of telo-
merase activity.
Ribozymes are catalytic RNA molecules which can be
designed to specially cleave a target RNA sequence by
incorporating the flanking sequence complementary to
the target [8]. Like other ribozymes, HDV ribozyme has
this property. So it may have a potential application in
gene therapy in which an engineered ribozyme is direc-
ted to inhibit gene expression by targeting a specific
mRNA molecule.
As hepatocellular carcinoma is often associated with
the infection of HBV and HDV, The facts that HDV
ribozyme derived from HDV and that pathogen natu-
rally infects and replicates in hepatocytes suggest that it
can be used to control gene expression in human cells.
T h eH D Vr i b o z y m ei sa c t i v ein vitro in the absence of
any proteins, it is the only known example of a catalytic
RNA associated with an animal virus. there are no
known homologues of HDV ribozymes, and sequence
variation of the HDV ribozymes in clinical isolates is
minimal.
Then we imagine whether HDV ribozyme can be used
to inhibit hepatocellular carcinoma. In the present study
we designed a HDV ribozyme against RNA component
of human telomerase in hepatocellular carcinoma cell
lines, as well as in normal hepatocytes and other can-
cers, then examined the function of the HDV ribozyme
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Methods
The bel7402, HCT116 cells were given by Department
of molecular Biology, Shandong University, DNA of
HDV ribozyme was synthesized by Shanghai Biosun
Sci&Tech. Co. LTD. Recombinant plasmid pBBS212
containing hTR gene was provided by Geron Company.
Design and synthesis of HDV ribozyme
It was demonstrated that antigenomic ribozyme of HDV
(g.RZ 1/84) is composed of 84 nucleotides [9]. It com-
posed four stems (P1-P4), two loops and three junctions.
As seen in Figure 1.
gRZ.1/84 can cleave 8-13 nt substrate by inter-mole-
cular cleavage [10], the substrate must integrate with P1
stem of HDV ribozyme through base-pairing before
cleavage, only 7 nt base pairing are needed, then the
cleavage can occur. In P1 stem G.U wobbling pair is
essential for the activity of gRZ.1/84 and cannot be
changed. The other 6 nucleotides can be changed, but
the change must keep Waston-Crick pairing to substrate
[11-13]. P4 stem isnot essential and can be deleted for
easier access of ribozyme to substrate [14]. The activities
of modified ribozyme do not decrease, but sometimes
increase [15,16].
We chose 12-84 nt of g.RZ 1/84, deleted 16 nt from
P4 stem, and changed 6 nt of P1 stem from CCGACC
to GGUUGA, only keeping G.U wobbling pair, to meet
the need of cleavage of telomerase. We called the new
ribozyme g. RZ57. The double-sranded DNA of g. RZ57
was synthesized with ApaΙ and HindIII protruding ends.
Their sequences are as follows: 5’ AGCTT GGGAC
CACCA CCACG CGGAC GCAAG AAGGG CAAGC
GGCAA CGCAA GGCAA AGGGACCC CCC 3’ and 5’
A CCCTG GTGGT GGTGC GCCTG GCTGG TCCCG
TTCGC CGTTG CGTTC CGTTT CCCTG GG GGG 3’.
The predicted secondary structure of g. RZ57 are seen
in Figure 2.
After annealing, the fragments were ligated to ApaΙ
and HindIII co-digested PGEM- 7Zf (+). This plasmid
was denoted as PGEM.RZ. It is the in vitro plasmid of
HDV ribozyme. We also ligated the fragments to ApaΙ
and HindIII co-digested pcDNA3.1 (+). This plasmid
was denoted as pcDNA.RZ. It is the eukaryotic expres-
sion plasmid of HDV ribozyme.
Telomerase RNA plasmid construction
We cloned a portion of hTR component containing a
telomeric template element using
RT-PCR. In normal conditions, only inhibition of the
template region can lead to the inhibition of telomerase
activity. we clone a portion ranging from 19 nt to 88 nt
of hTR. There are 14 template regions (GUC sequence)
in this portion. We chose one site (47-50 nt) as cleavage
site. Primers for RT-PCR were as follows: 5’CTGGG
A G G G GT G G T GG C C A T3 ’(upstream) and 5’GGAGC
AAAAG CACGG CGCCT 3’ (downstream). 70 nt
Figure 1 Structure of antigenomic ribozyme of HDV (g.RZ 1/84).
Figure 2 The secondary structure of HDV ribozyme annealed
to the hTR, the target site GUC is just above the arrow, the
arrow indicates the site of cleavage.
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min; 94°C 2 min; 94°C 30 s, 55°C 30 s, 72°C 1 min). The
purified products were cloned into PGEM-T plasmid.
The resulting plasmid is denoted as PGEM.hTR. The
obtained human telomerase component was verified by
DNA sequencing.
In vitro cleavage reaction by ribozymes
Plasmid PGEM.RZ was linerized by SmaI, and PGEM.
hTR by EcoRV respectively. Then in vitro transcription
kit Riboprobe
® system- Sp6/T7 P1460 was used to tran-
script plasmids. We got a 80 nt RNA fragment of HDV
RZ(part is carrier fragment), and a 90 nt RNA fragment
of hTR (part is carrier fragment).
After hTR was radioactively labeled, we mixed the
ribozyme and substrate RNA(molar ratio 2.5:1, 5:1, 10:1,
20:1 respectively) at different temperature in a 20 μl
reaction volume containing 50 mM Tris-HCl(PH 7.5)
and 1 mM EDTA.
At different time 5 μl mixture was taken to electro-
phorese on 5% agorose gel, and the results were quanti-
tatively analyzed by autoradiography to calculate the
cleavage rates.
Transfection of bel-7402 and HCT116 cells
The bel7402, HCT116 cells (5 × 10
4) were seeded in
6-well plates, a day before transfection. Lipofections of
heptocellular carcinoma 7402 cells, colon cancer cells
HCT116 and normal human heptaocyte L02 with both
the 10 μg pcDNA.RZ vector and PGEM-7Zf (+) were
performed according to the protocol recommended by
the manufacturer (Life Technologies, Inc). After 24 h,
48 h, 72 h, all cells were scored for apoptosis, telomer-
ase activity assay and respectively.
Telomerase activity assay
Cellular telomerase activity was measured with TRAP-
ELISA kit (Roche Diagnostics GmbH). The cells (about
10
5-10
6) were collected and washed twice by PBS, lyzed
in 200 μl of cell lysis buffer, incubated at 4°C for 30
min, then centrifuged at 16,000 rpm for 10 min.
Telomerase activity was determined before and after
the induction of ribozyme plasmid. The telomerase
activity A was semiquantified photometrically at 450 nm
and 690 nm. A = A450-A690. The results were tested by
t test.
Northern blot analysis
Twenty micrograms of total RNA was loaded on 1%
agarose/formaldehyde gel, electrophoresed, and then
mounted on a nylon membrane by capillary transferA
single - strand probe was generated by RT-PCR of a 184
bp fragment by of hTR cDNA by digestion of Recombi-
nant plasmid pBBS212 containing hTR gene (provided
by Geron Company) with EcoRI. The purified fragment
was mixed with 15 pmol of dNTP and 25 Ci of [a- 32P]
dCTP (NEN Life Sciences) in 20 mM Tris-HCl, 50 mM
KCl, pH 8.4, 1.5 M MgCl2, containing 0.2 g/L hTR for-
ward primer 5’-CTGGG AGGGG TGGTG GCCAT-3’)
and 2.5 U of Ex Taq DNA polymerase (TaKaRa Biotech,
Shiga, Japan).
Amplification was carried out with 34 cycles of dena-
turation at 94°C for 30 seconds,
annealing at 60°C for 30 seconds, and extension at
72°C for 1 minute. After purification, the hTR probes
were heated at 100°C for 5 minutes and immediately
added to hybridization reaction.
Cell cycle and apoptotic rate analysis
Growing cells (about 2 × 10
6) were collected and fixed
with 70% cold ethanol for at least 12 h, then were
stained by propidium iodide. Cells were analyzed for the
cell distribution and apoptotic rate by DNA analysis
using FCM.
Statistical Analysis
The student’st e s ta n dX
2 test were used to evaluate the
statistical significance of the results. All analyses were
performed with SPSS statistical software.
Results
In vitro cleavage reaction
According to this research, the most suitable temperature
for HDV RZ cleavage is 45°C, a little lower than hammer-
head RZ (55°C). RNA will degrade higher than 45°C. The
most suitable molar ratio is 5:1 and the most suitable
cleavage time is two hours. The maximum cleavage
ration is 70.4%. Lengthening the reaction time or increas-
ing the RZ/hTR ratio cannot increase the cleavage ration.
In the case of control RZ, no obvious catalytic activity
was detected. One cleavage process was shown at molar
ratio 5:1 and at the temperature 45°C in Figure 3.
The telomerase activity
Cellular telomerase activityo fe u k a r y o t i cb e l 7 4 0 2 - R Z ,
HCT116-RZ and L02-RZ are shown in table 1. The telo-
merase activity of bel7402-RZ cells dropped continu-
ously. It dropped to 10% of that before after 72 hours.
While the L02-RZ cells almost have no change, as seen
in table 1.
Northern blot analysis
Ribozyme transfected bel7402 cells and HCT116 cells
showed decrease of hTR RNA. In ribozyme transfected
bel7402 cells, the uncut hTR decreased to 1/25 of the
original, in HCT116 cells, the uncut hTR decreased to
1/20 of the original; while the others did not obviously
decrease (seen in Figure 4).
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Ribozyme transfected 7402 cells and HCT116 cells dis-
played an increased percentage of cells in the G0/G1
phase and apoptotic rate, as compared with other cell
lines, The results are shown in table 2 and Figure 5.
Discussion
Telomerase activity increases in most malignant tumors.
To inhibit the telomerase activity is a new method for
tumor therapy [17]. Human telomerase RNA is closely
associated with telomerase activity. The template region
is crucial for enzyme activity, and this site is required
for de novo synthesis of telomeric repeats by telomerase
[18,19]. Inhibition for distant region from template
region has no effect on telomerase activity, so we chose
the template region, GUC sequence, as a cleavage site
[20,21].
Autexier [22]et al have proved that the functional area
is located between 44 to 203 nt, in the experiment we
cleave the template region located from 47 to 50 nt on
hTR, and it should cause the significant reduction in tel-
omerase activity.
In transacting gRZ.57, 16 nt was deleted from P4
stem, 6 base pairs in P1 were changed except G.U wob-
bling pair to meet the base pairing interaction between
ribozyme and the substrate. The designed gRZ.57 exhib-
ited cleavage activity.
We found that the extent of cleavage is about 70.4% in
our research, no matter we increase the concentration of
ribozyme or lengthen the time, it suggests that: (1) Ribo-
zyme might conform differently and cannot combine
Figure 3 In vitro cleavage in a mixture of the RNA substrate
and RZ at molar ratio 5:1 and at 45°C, after 0,1, 2, 3 hours of
incubation respectively. (lanes 1-4, lane C is the control lane; 1.
hTR+ RZ (0 h); 2. hTR+ RZ(1 h); 3. hTR+ RZ (2 h). 4. hTR+ RZ (3 h)).
Table 1 The telomerase activity of ribozyme tranfected cells
0h r 2 4h r 4 8h r 7 2h r 9 6h r
bel7402-RZ 0.87 ± 0.09 0.59 ± 0.05 0.28 ± 0.06* 0.08 ± 0.01* 0.08 ± 0.01*
HCT116-RZ 0.84 ± 0.10 0.65 ± 0.07 0.32 ± 0.08* 0.13 ± 0.05* 0.10 ± 0.03*
L02-PGEM 0.85 ± 0.09 0.84 ± 0.10 0.81 ± 0.06 0.80 ± 0.05 0.78 ± 0.04
L02-RZ 0.87 ± 0.09 0.80 ± 0.12 0.78 ± 0.09 0.75 ± 0.11 0.72 ± 0.07
bel 7402- PGEM 0.87 ± 0.09 0.81 ± 0.07 0.82 ± 0.03 0.83 ± 0.04 0.82 ± 0.04
HCT-PGEM 0.89 ± 0.11 0.85 ± 0.14 0.80 ± 0.08 0.77 ± 0.06 0.71 ± 0.10
*P < 0.01.
Figure 4 Time course of Northern blot analysis of hTR RNA in
different cell lines after transfection 0, 24, 36, 72 hours
respectively.
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of the ribozyme, not P1 stem. (3) A part of ribozyme-
substrate complex adopts other conformation, and
undergoes cleavage at a very low rate [23,24].
After eukaryotic expression plasmid of ribozyme was
induced into 7402 cells and HCT116 cells, telomerase
activity attenuated to 10% of that before, the telomerase
activity of control cells doesn’t change. This suggest that
HDV ribozyme can cleave the hTR component as ham-
merhead ribozyme does, but its cleaving efficacy of is
higher than that of hammerhead ribozyme [25].
Compared with L02 hepatocytes, bel 7402-RZ and
HCT116-RZ cells mainly showed both Spontaneous apop-
tosis and blockage of cell cycle. In immortal cells, it has
been shown that telomerase activity is associated with the
cell cycle [26]. The highest telomerase activity is found in
the S phase of cell cycle [27], whereas quiescent cells do
not possess telomerase activity at a detectable level. Can-
cer cells escape senescence through both cell cycle check-
point inactivation and the activation of telomerase. In
addition to structural constraints [28], active telomerase is
one possible factor to physically shield the telomeric
G-rich singlestranded overhang. The presence of free
G-rich single-stranded telomeric DNA within the nucleus
was found sufficient to trigger cell cycle arrest in U87 glio-
blastoma cells and in human fibroblasts [29]. One might
speculate that inhibition of telomerase might increase the
probability that at some point in the cell cycle a free telo-
meric overhang becomes exposed to the nucleoplasm and
could trigger cell cycle arrest or apoptosis.
It was also reported that the content of telomerase
RNA in cells was not parallel to the telomerase activ-
ity [30]. In previous studies, hTR could be measured
in cells, but there was no telomerase activity mea-
sured. Or, the hTR content in cells was measured
high, but the telomerase activity was low. These
results indicate that hTR is not the only determinant
of telomerase activity. The catalytic protein subunits
are believed to be the key determinant of telomerase
activity [31].
In our northern, the uncut hTR decreased to 1/25 and
1/20 of the original in ribozyme transfected bel7402
Table 2 Cell cycle distribution and apoptotic rate in ribozyme-transfected and control cells
Cell line Cell cycle distribution (%) Apoptotic rate (%)
G0/G1 S G2/M 24 hr 48 hr 72 hr
L02-RZ 50.8 ± 4.9 28.1 ± 5.9 21.1 ± 3. 7 1.7 ± 0.1 2.0 ± 0.2 2.3 ± 0.4
bel 7402-RZ 71.7 ± 6.1 12.1 ± 2.0 17.0 ± 2.9 14.3 ± 2.3 35.2* ± 4.9 75.5* ± 6.5
HCT116-RZ 56.2 ± 5.5 17.5 ± 2.5 26.3 ± 3.7 9.6 ± 1.9 20.4* ± 3.4 59.7* ± 5.7
bel 7402-PGEM 58.0 ± 5.0 19.2 ± 2.7 22.6 ± 3.0 0.8 ± 0.05 2.6 ± 0.7 4.3 ± 1.1
L02-PGEM 55.0 ± 6.9 27.8 ± 4.8 7.2 ± 2.3 2.3 ± 0.9 5.8 ± 1.0 8.6 ± 0.7
HCT116- PGEM 60.1 ± 10.2 18.3 ± 7.4 22.6 ± 3.7 2.5 ± 0.3 3.4 ± 0.7 5.2 ± 0.6
Figure 5 Apoptotic rate of ribozyme-transfected and PGEM vector transfected cells (1-6). 1 bel 7402 +PGEM-7Zf (+); 2. bel 7402 +RZ; 3.
HCT116+RZ; 4. HCT116+ PGEM-7Zf (+); 5. L02+RZ; 6. L02+ PGEM-7Zf (+).
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activity drop to 1/10 and 1/8 respectively of the original.
The results confirm the discrepancy of telomerase activ-
ity with telomerase RNA content.
Ribozyme-transfected bel7402 cells and HCT116 cells
showed G1/G0 arrest and proliferation inhibition, and
75% cells showed apoptosis at 96 h. This is consistent
with reduction of telomerase activity.
Our results suggest that diminution of telomerase can
interfere with cancer cell growth and induce cell death,
presumably through apoptosis. Emerging evidence
revealed that telomerase activity is associated with
increased cellular resistance to apoptosis [29,32,33]. Tel-
omerase activity might therefore play some role in apop-
tosis-controlling mechanisms and inhibition of
telomerase by ribozyme might impair this pathway.
Conclusion
gRZ.57 we designed in the research is effective against
the hTR, it is a promising agent for tumor therapy.
HDV ribozyme may be used to cleave other molecules,
such as viruses [34].
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